Form 4: NRX Pharmaceuticals Director Jonathan Javitt Acquires 40,000 Shares

Jonathan Javitt, a director and officer of NRX Pharmaceuticals, purchased 40,000 shares of common stock at $1.17 per share on December 17, 2024.

Summary

• Jonathan Javitt, a director, 10% owner, and Chairman and Chief Scientist of NRX Pharmaceuticals, acquired 40,000 shares of common stock on December 17, 2024.
• The shares were purchased at a price of $1.17 per share.
• Following the transaction, Mr. Javitt directly owns 84,634 shares.
• He also indirectly owns 1,260,000 shares through the Jonathan Javitt Living Trust, 142,200 shares through the Javitt 2012 Irrevocable Dynasty Trust, and 30,000 shares through the Jonathan Javitt Donor Advised Fund.

Sentiment

Score: 6

Explanation: The document is a routine filing of an insider transaction. It is neither particularly positive nor negative, but the purchase of shares by a director could be seen as a slightly positive sign.

Positives

• The purchase of shares by a director and officer may signal confidence in the company's future prospects.
• The transaction increases Mr. Javitt's stake in the company, aligning his interests with those of other shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the transactions of key personnel.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The level of detail provided in this filing is consistent with SEC requirements for reporting changes in beneficial ownership.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the insider purchase.

Key Dates

Keywords

NRX Pharmaceuticals, Jonathan Javitt, insider trading, share purchase, common stock, beneficial ownership, Form 4